US FDA: Gradual restart of surveillance inspections
The US FDA is planning a gradual re-start of on-site surveillance inspections in cooperation with the Centers for Disease Control and Prevention (CDC).
Since March due to COVID-19 only mission-critical inspections abroad as well as domestic for-cause inspections have been carried out. Continuously, alternatives such as the evaluation of company records should still be used as far as possible. Together with the CDC, further action based on scientific data and in accordance with the White House Guidelines for the reopening of the USA is planned. This should ensure that inspections are conducted safely.
Source:
Meet the GMP Compliance Adviser
The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business.
The demo access is non-binding and ends automatically.
You may also be interested in the following articles:
